The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Spinal Haemorrhage During Anticoagulant Regimen for Thromboprophylaxis: A Unique Form of Central Nervous System Haemorrhage
JNNP 83:746-752, Furlan, J.C.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians
Stroke 39:227-230,7, Gattellari,M.,et al, 2008
Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
Stroke 39:1901-1910, Stroke Risk in Atrial Fibrillation Working Group, 2008
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
Stroke 38:2459-2463,2409, Baruch,L.,et al, 2007
Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006
Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation: Yes
Stroke 37:3052-3053,3056, Chamorro,., 2006
Immediate Angicoagulation for Acute Stroke in Atrial Fibrillation: No
Stroke 37:3054-3055,3056, Sandercock,P., 2006
Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients with Nonrheumatic ATrial Fibrillation and a History of Stroke or Transient Ischemic Attack
Stroke 36:914-915, Saxena,R. &Koudstaal,P.J., 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Combined Anticoagulant-Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients
Stroke 35:2362-2367, Shireman,T.I.,et al, 2004
A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community
JAMA 290:1049-1056,1093, Wang,T.J.,et al, 2003
Stroke Prevention in Atrial Fibrillation
JAMA 290:1093-1095, Waldo,A.L., 2003
A 50-Year-Old Woman With Atrial Fibrillation
JAMA 290:2182-2189, Singer,D.E., 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
New Evidence for Stroke Prevention
JAMA 288:1388-1395, Straus,S.E.,et al, 2002
Prevalence of Atrial Fibrillation and Antithrombotic Prophylaxis in Emergency Department Patients
Stroke 33:2664-2669, Scott,P.A.,et al, 2002
Atrial Fibrillation, Stroke, and Acute Antithrombotic Therapy
Stroke 33;2722-2727, Hart,R.G.,et al, 2002
Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial
Stroke 32:2333-2337, Saxena,R.,et al, 2001
Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients with Atrial Fibrillation?
Stroke 32:2828-2832, Evans,A.,et al, 2001
Decision Analysis and Guidelines for Anticoagulant Therapy to Prevent Stroke in Patients with Atrial Fibrillation
Lancet 355:956-962, Thomson,R.,et al, 2000
Anticoagulation for Chronic Atrial Fibrillation
JAMA 283:2901-2903, Stern,S.,et al, 2000
Prospective Cohort Study to Determine if Trial Efficacy of Anticoagulation for Stroke Prevention in Atrial Fibrillation Translates Into Clinical Effectiveness
BMJ 320 :1236-1239,1219, Kalra,L.,et al, 2000
Low Molecular-Weight Heparin Versus Aspirin in Patients With Acute Ischaemic Stroke and Atrial Fibrillation: A Double-Blind Randomised Study
Lancet 355:1205-1210, Berge,E.,et al, 2000
Prevention of Ischaemic Stroke
BMJ 321:1455-1459, Gubitz,G. & Sandercock,P., 2000
Oral Anticoagulation in Patients with Atrial Fibrillation:Adherence with Guidelines in an Elderly Cohort
Am J Med 106:165-171, White,R.H.,et al, 1999
Choosing Antithrombotic Therapy for Elderly Patients with Atrial Fibrillation Who are at Risk for Falls
Arch Int Med 159:677-685, Man-Son-Hing,M.,et al, 1999
Risk Assessment and Anticoagulation for Primary Stroke Prevention in Atrial Fibrillation
Stroke 30:1218-1222, Kalra,L.,et al, 1999
A Patient Decision Aid Regarding Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation, A Randomized Controlled Trial
JAMA 282:737-743,779, Man-Son-Hing,M.,et al, 1999
When Should Heparin be Given to Patients with Atrial Fibrillation-Related Embolic Brain Infarcts?
Arch Neurol 56:1059-1060, Caplan,L.R., 1999
Heparin in Acute Stroke with Atrial Fibrillation, Clinical Relevance of Very Early Treatment
Arch Neurol 56:1098-1102,1059, Chamorro,A.,et al, 1999
Prognosis of Patients with Symptomatic Vertebral or Basilar Artery Stenosis
WASID Study Group, Stroke 29:1389-13921998., , 1998
Cost-Effectiveness of Anticoagulation in Nonrheumatic A Fib in the Primary Prevention of Ischemic Stroke
Stroke 29:1827-1832, Lightowlers,S.&McGuire,A., 1998
Fixed Minidose Warfarin & Aspirin Alone & in Comb vs Adjusted-Dose Warfarin for Stroke Prevent in Atrial Fib
Arch Int Med 158:1513-1521, 14871998., Gullov,A.L.,et al, 1998
Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
Neurol 51:674-681, Hart,R.G.,et al, 1998